So grab that cup of stimulation and get started. Our flavor today is pumpkin spice, for those tracking our habits. Now, though, the time has come to get busy. So please grab your own cup and dig in to the items of interest assembled below. We hope you have a wonderful day, and please do keep in touch. …

Delaware’s highest court agreed to hear an appeal by GSK and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer, Reuters writes. GSK, Pfizer, Sanofi, and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony on the alleged cancer link, which the companies argue is not supported by sound scientific methods. Without that testimony, the lawsuits cannot go forward. The drugmakers won a significant victory in 2022, when a federal judge in Florida rejected the plaintiffs’ expert witnesses in about 50,000 cases on the grounds that they did not use reliable scientific methods. Some of the Florida cases are being appealed, and the vast majority of the remaining cases are in Delaware.

Neurocrine Biosciences reported that the lowest dose of an experimental pill for schizophrenia reduced psychosis reported by patients in a mid-stage study, but higher doses of the drug also tested were ineffective, STAT informs us. The company said the study results supported advancing the medicine into Phase 3 studies next year. Investors viewed the mixed data with more concern, sending Neurocrine stock down 18% in early trading. The drug belongs to an emerging class of neuropsychiatric medicines that target muscarinic receptors in the brain. This type of drug has garnered a lot of attention due to the acquisitions of Karuna Therapeutics ($14 billion) and Cerevel Therapeutics ($8.7 billion) by Bristol Myers Squibb and AbbVie, respectively.

Continue to STAT+ to read the full story…

This advanced technology promises to revolutionise cancer treatment, offering patients more precise, effective, and potentially life-saving care, according to Paula Agbowu, the hospital’s director of engineering services.

“Coming up is the acquisition of a linear accelerator machine that will be used to help treat some of our oncology cases,” Christine Greenidge, the hospital’s chief operating officer, said during this week’s Pulse Radio programme.

The new linear accelerator, expected to be operational by year’s end, represents a significant upgrade from the hospital’s current cobalt-based technology. It will enable oncologists to deliver highly targeted radiation therapy, potentially improving outcomes and reducing side effects for cancer patients, according to Agbowu.

The director of engineering services highlighted the transformative impact this acquisition will have on patient care.

“The actual linear accelerator will mean that the kind of treatment that we will be able to afford our patients will be much more enhanced than the treatment that we had before,” she stated. “This is an upgrade and a step up from what we had in place before.”

The installation of this sophisticated equipment is part of a broader £130 million investment in the hospital’s infrastructure and technology. This substantial funding, announced earlier this year by the Ministry of Health, underscores the government’s commitment to enhancing healthcare services across the island. The first tranche of funding is expected to be released in the coming weeks, Agbowu revealed.

The hospital is undertaking comprehensive infrastructure improvements, including modifications to the treatment bunker, electrical systems, and IT infrastructure. Crucially, the QEH is investing in its staff to ensure they can maximise the potential of this new technology. Physicists, radiographers, and oncologists are already engaged in intensive training programmes to familiarise themselves with the linear accelerator’s advanced capabilities.

Meanwhile, the QEH is undertaking an ambitious initiative to transform healthcare delivery, making it more accessible and efficient for patients.

At the heart of this overhaul is an expansion of telehealth services, allowing remote monitoring of patients with chronic conditions such as congestive heart failure. This innovative approach enables medical staff to track vital signs from patients’ homes, reducing the need for frequent hospital visits and allowing for timely interventions.

QEH is also transitioning to electronic medical records, streamlining appointment management and granting patients easier access to their health information. The comprehensive upgrade extends to health information systems, enhancing both patient care and data protection. These initiatives are part of the $130 million capital expenditure programme designed to acquire new technology and upgrade existing systems at the hospital.

The post QEH on track to revolutionise cancer care with linear accelerator appeared first on Barbados Today.

The product is a generic equivalent of Alphagan P Ophthalmic Solution, 0.1%, of AbbVie Inc. It will be manufactured at Lupin's Pithampur facility in India.

Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Read also: Lupin alliance partner ForDoz gets USFDA nod for Doxorubicin Hydrochloride Liposome Injection

Open-Angle Glaucoma is the most common form of glaucoma, a group of eye conditions that damage the optic nerve, leading to vision loss. This damage is often caused by abnormally high pressure in the eye (intraocular pressure), though normal-pressure glaucoma can also occur.

Medical Dialogues team had earlier reported that Lupin Limited had received USFDA nod for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004%(Ionic Buffered Solution). Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Read also: Lupin bags USFDA nod for Travoprost Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution (RLD Alphagan P) had an estimated annual sales of USD178.5 million in the U.S. (IQVIA MAT June 2024).

Lupin Limited is a global pharmaceutical Company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a presence in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.

Also Read:6 medicines of Alembic Pharma received USFDA nod during Q2FY24

As parents, we understand the importance of protecting our children’s eyes from the sun’s harmful rays, but what about the harmful effects of blue light? Blue light, a colour in the visible light spectrum, is everywhere. Believe it or not, sunlight...

Monkeypox is caused by the Orthopoxvirus, which is related to the smallpox family of disorders native to the African continent. However, this virus has recently spread throughout Africa and to some countries in Europe. Monkeypox (mpox)is capable...